论文部分内容阅读
为探讨恶性淋巴瘤感染ＨＴＬＶ－Ⅰ的频度，首次采用ＨＴＬＶ－ⅠＥｎｖｇｐ４６的单克隆抗体６Ｃ２对中国沈阳及日本鹿儿岛地区恶性淋巴瘤进行了免疫组织化学（组化）研究。沈阳地区７０例恶性淋巴瘤中６例（８．６％）阳性。其中成人Ｔ细胞白血病（ＡＴＬ）淋巴瘤１例，霍奇金病３例，Ｋｉ－１大细胞未分化淋巴瘤１例，ＮＫ／Ｔ细胞淋巴瘤１例。鹿儿岛地区的Ｔ细胞淋巴瘤中，ＡＴＬ淋巴瘤型３３例中３０例（９１％），透明细胞型１６例中７例（４４％）阳性，其它型１３例中７例（５４％）阳性。６Ｃ２免疫组化方法为回顾性研究肿瘤中是否有ＨＴＬＶ－Ⅰ感染提供了重要手段。
To investigate the frequency of HTLV-Ⅰ infection by malignant lymphoma, the first time using HTLV-ⅠEnvgp46 monoclonal antibody 6C2 in Shenyang, China and Japan’s Kagoshima region of malignant lymphoma immunohistochemistry (histochemical) study. Shenyang, 70 cases of malignant lymphoma in 6 cases (8.6%) were positive. Including adult T cell leukemia (ATL) lymphoma in 1 case, Hodgkin’s disease in 3 cases, Ki-1 large cell undifferentiated lymphoma in 1 case, NK / T cell lymphoma in 1 case. In Kagoshima T-cell lymphoma, 30 (91%) were found in 33 cases of ATL lymphoma, 7 (44%) in 16 cases of clear cell type and 7 (54%) in 13 cases of other types, Positive. 6C2 immunohistochemical method for retrospective study of HTLV-Ⅰ tumor infection provides an important means of infection.